The power of our people
Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.
Search
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager: DLL3/CD3 T-cell engager
“Rare diseases are quite common”
Rare diseases are individually rare but collectively affect millions of people worldwide. Yet, they remain under-researched and are often misdiagnosed.
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
FDA-Fast-Track-chronic-kidney-disease
FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition
Collaborating for social impact
Societal challenges require collective action and Making More Health Together is connecting changemakers to drive collaborations for more social impact
GPP Forum Article - Frida Dunger Johnsson, Executive Director, IFPA
Frida Dunger Johnsson, Executive Director of IFPA and panelist at the generalized pustular psoriasis (GPP) Forum, reflects on a momentous day
Solid Fundations | Bioxcellence | Boehringer Ingelheim
Discover BioXcellence's innovative biopharmaceutical contract manufacturing services, built on a proven track record & solid foundation. Explore now!
Boehringer Ingelheim acquires Nerio Therapeutics
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
U.S. FDA grants priority review for spesolimab in GPP
U.S. FDA grants priority review for spesolimab in the treatment of patients with generalized pustular psoriasis
emperor-preserved-chmp-positive-opinion
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
B7-H6/CD3 T-Cell Engager
B7-H6/CD3 T-Cell Engager
KISIMA® cancer vaccine
KISIMA® Cancer Vaccine
European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares
European Commission grants marketing authorization for spesolimab, the first specific treatment option for generalized pustular psoriasis flares in adults
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
Targeting Tumor Stroma
Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
VSV-GP
VSV-GP
empa-reg-outcome-recurrent-events
EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
The chronic nature of generalized pustular psoriasis
Understanding the impact of the physical and psychological symptoms of this chronic disease.
Facing Pulmonary Fibrosis
Steve Jones talks about his experience facing his pulmonary fibrosis diagnosis.
Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.